A total of 2000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are enrolled. All the patients will receive original antiviral treatment for the following 10 years. Patients will be assessed at baseline and at every six months for blood count, liver function test, alpha fetoprotein (AFP), prothrombin time, liver ultrasonography, liver stiffness measurement (LSM), Hepatitis B virus (HBV) DNA and HBV serological markers. HBV-related endpoint events, including cirrhosis decompensations (ascites, esophageal variceal bleeding and hepatic encephalopathy), hepatocellular carcinoma (HCC), liver transplantation and liver-related death, will be collected during follow-up.
No.
Study Type
OBSERVATIONAL
Enrollment
2,000
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Wuxi Hisky Medical Technologies Co., Ltd.
Wuxi, Jiangsu, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Hangzhou Choutu Technology Co.,Ltd.
Hangzhou, Zhejiang, China
HBV-related clinical endpoint events, including liver decompensations (ascites, esophageal variceal bleeding and hepatic encephalopathy), HCC, liver transplantation and liver-related death
Incidence of HBV-related clinical endpoint events during follow-ups
Time frame: 1 to 10 years
Predicted probability of HBV-related clinical endpoint events
The predicted probability is measured by histological prediction model or non-invasive prediction model
Time frame: 1 to 10 years
Predicted probability of HBV-induced fibrosis/cirrhosis regression
The predicted probability is measured by histological prediction model or non-invasive prediction model
Time frame: 1 to 10 years
Percentage of HBV-induced liver fibrosis/cirrhosis regression
Liver fibrosis regression was defined as decrease \>= 1 point by Ishak fibrosis scoring system (range from 0 to 6, higher values represent a worse outcome) or Predominantly Regressive in P-I-R ( predominantly progressive, indeterminate and predominately regressive) score
Time frame: 1 to 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.